Review Article
Meta-Analysis of the Relationship between NM23 Expression to Gastric Cancer Risk and Clinical Features
Table 2
Overall analysis of CD133 expression association with clinical features.
| | OR | 95% CI | | | |
| Gastric cancer risk | 0.168 | 0.063–0.443 | <0.001 | 50.20% | 0.134 | N stage | 0.493 | 0.269–0.904 | 0.022 | 86.10% | 0.052 | TNM stage | 0.47 | 0.32–0.70 | <0.001 | 82.20% | 0.401 | Histological grade | 0.476 | 0.319–0.711 | 0.001 | 60.30% | 0.294 | T stage | 0.889 | 0.500–1.583 | 0.690 | 69.10% | 0.606 | Lymphatic invasion | 0.801 | 0.343–1.874 | 0.609 | 73.00% | 0.437 | Vascular invasion | 0.902 | 0.429–1.899 | 0.787 | 58.80% | 0.835 | 5-Year OS rate | 0.478 | 0.194–1.181 | 0.110 | 89.60% | 0.074 |
|
|
, the value of Egger linear regression test for evaluating publication bias.
|